INKT
INKT
NASDAQ · Biotechnology

Mink Therapeutics Inc

$10.51
-0.54 (-4.89%)
As of May 16, 2:20 AM ET ·
Financial Highlights (FY 2025)
Revenue
45.10M
Net Income
3.70M
Gross Margin
30.2%
Profit Margin
8.2%
Rev Growth
+4.3%
D/E Ratio
0.88
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 30.2% 30.2% 30.2%
Operating Margin 8.6% 8.8% 7.8%
Profit Margin 8.2% 7.2% 6.5%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 45.10M 46.49M 39.49M
Gross Profit 13.63M 14.05M 11.94M
Operating Income 3.90M 4.10M 3.06M
Net Income 3.70M 3.34M 2.56M
Gross Margin 30.2% 30.2% 30.2%
Operating Margin 8.6% 8.8% 7.8%
Profit Margin 8.2% 7.2% 6.5%
Rev Growth +4.3% +20.2% +6.0%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 21.44M 23.91M 26.79M
Total Equity 24.25M 22.68M 23.45M
D/E Ratio 0.88 1.05 1.14
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 5.80M 5.78M 5.15M
Free Cash Flow 3.02M 2.12M 2.20M